王前奔，教授，博士生導(dǎo)師。2002年獲美國馬里蘭大學(xué)巴爾的摩分校博士學(xué)位，2003–2008年在哈佛大學(xué)Dana-Farber腫瘤研究所從事博士后研究，并任哈佛大學(xué)醫(yī)學(xué)院講師。此后歷任美國俄亥俄州立大學(xué)醫(yī)學(xué)院助理教授（2008-2013）、副教授（2013-2017），以及杜克大學(xué)醫(yī)學(xué)院正教授和冠名講席教授（2017-2025）。曾主持多項(xiàng)美國NIH U54、R01和DoD研究項(xiàng)目。2025年獲美國基礎(chǔ)泌尿科學(xué)研究學(xué)會(huì)（SBUR）杰出研究成就獎(jiǎng)。
      院校引進(jìn)人才，2025年加入院校，曾在杜克大學(xué)醫(yī)學(xué)院任終身冠名講席教授。

長期從事疾病相關(guān)的基因調(diào)控機(jī)制與RNA靶向基因治療研究，在激素依賴性腫瘤轉(zhuǎn)錄與表觀遺傳調(diào)控領(lǐng)域取得系統(tǒng)性成果。近年來，將CRISPR/Cas13 RNA編輯技術(shù)與脂質(zhì)納米顆粒（LNP）遞送系統(tǒng)相結(jié)合，構(gòu)建了新型RNA精準(zhǔn)治療平臺(tái)，在癌癥轉(zhuǎn)移、耐藥機(jī)制、免疫逃逸以及冠狀病毒感染及其后期組織修復(fù)等領(lǐng)域取得了重要突破。相關(guān)成果發(fā)表于Cell、Molecular Cell、Nature Genetics、Nature Chemical Biology、Cell Research、PNAS、Nature Communications、EMBO Journal、Cancer Research、Advanced Science、Nano Research等國際著名期刊。現(xiàn)任美國基礎(chǔ)泌尿科學(xué)研究學(xué)會(huì)（SBUR）常務(wù)董事、執(zhí)行委員會(huì)委員。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

1. Cui Z#, Huang F, Fang K, Yan J, Zhang Y, Kang DD, Zhou Y, Zhao Y, Everitt JI, Hankey W, Armstrong AJ, Huang J, Wang H, Jin VX, Dong Y* and Wang Q*. SCORT-Cas13d nanotherapy precisely targets the ‘undruggable’ transcription factor HoxB13 in metastatic prostate cancer in vivo. Advanced Science, 2025 Jun;12(23):e2417605. (IF=14.1)

2 . Cui Z#, Liu T, Bacon R, Zhao Y, Everitt JI, Yan J, Chen L, Huang J, Wang H, Dong Y*, Jin VX*, Liu SL*, Wang Q*. Single-dose cathepsin L CRISPR nanotherapy mitigates PASC-like lung damage in hamsters. Nano Research, 2025 Sep;18(9):94907695. (IF=9)

3. Cui Z#, Zeng C, Huang F, Yuan F, Yan J, Zhao Y, Zhou Y, Hankey W, Jin VX, Huang J, Staats HF, Everitt JI, Sempowski GD, Wang H, Dong Y*, Liu SL* and Wang Q*.  Cas13d knockdown of lung protease Ctsl prevents and treats lethal SARS-CoV-2 infection. Nature Chemical Biology, 2022 Oct;18(10):1056-1064. (IF=14.8)

4. Li T#, Liu Q#, Chen Z#, Fang K, Huang F, Fu X, Wang Q*, and Jin VX*. Dynamic nucleosome landscape elicits a novel noncanonical GATA2 pioneer model. Nature Communications, 2022 Jun 7;13(1):3145. (IF=16.6)

5. Chen Z#*, Hankey W, Zhao Y, Groth J, Wang H, Huang J, Roeder RG, and Wang Q*. Transcriptional recycling assays identify PAF1 as a driver of RNA Pol II recycling. Nature Communications, 2021 Nov 3;12(1):6318. (IF=17.694)

6. Huang F#, Chen H#, Zhu X, Gong T, Li X, Hankey W, Ding D, Wang H, Chen Z*, Wang Q*, and Liu Z*. The oncogenic function of androgen receptor in esophageal squamous cell carcinoma is directed by GATA3. Cell Research, 2021 Mar;31(3):362-365. (IF= 46.351)

7. Chen Z#, Wu D, Thomas-Ahner JM, Lu C, Zhao P, Zhang Q, Geraghty C, Yan PS, Hankey W, Sunkel B, Cheng X, Antonarakis ES, Wang QE, Liu Z, Huang THM, Jin VX, Clinton SK, Luo J*, Huang J*, Wang Q*. Diverse AR-V7 cistromes in castration-resistant prostate cancer growth are governed by HoxB13. Proceedings of the National Academy of Sciences of the United States of America, 2018 Jun 26;115(26):6810-6815. (IF= 9.580, C100)

8. Chen K#, Chen Z#, Wu D, Zhang L, Lin X, Su J, Rodriguez B, Xi Y, Xia Z, Chen X, Shi X, Wang Q* and Li W*. Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes. Nature Genetics, 2015 Oct;47(10):1149-57. (IF=31.616, C100)

9. Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, Wang L, Sunkel B, Grenade C, Chen J, Zynger DL, Yan PS, Huang, J, Nephew KP, Huang THM, Lin S, Clinton SK, Li W, Jin VX and Wang Q. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. EMBO Journal, 2015 Feb 12;34(4):502-16 (IF=9.643, C100).

10. Wang Q#*, Li W#, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Wu T, Lupien M, Carroll JS, Manrai AK, J?nne OA, Balk SP, Mehra R, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS*, and Brown M*. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell, 2009 Jul 23;138(2):245-56. (IF=31.152, F1000, C100)